Skip to main content

Pretreatment with sufentanil reduces myoclonus after etomidate

Buy Article:

$51.00 plus tax (Refund Policy)



Myoclonic movements are a common problem during the induction of general anesthesia with etomidate. We investigated the influence of pretreatment with the opioid sufentanil on the incidence of etomidate-induced myoclonus. Methods:

Forty female patients (ASA physical status I–III) were randomly assigned to receive double-blinded either 0.3 µg kg−1 of sufentanil or placebo 150 s before the induction of sleep with 0.3 mg kg−1 of etomidate. The patients were observed for any myoclonic movement. Grade of dizziness, breathing frequency, non-invasive blood pressure and heart rate were measured during the study period. Results:

None of the 20 patients receiving sufentanil had myoclonic movements after the administration of etomidate, whereas 16 patients in the placebo group (80%) experienced such movements (P<0.01). No cases of apnoea before induction of sleep were seen in the sufentanil group. Conclusion:

Sufentanil 0.3 µg kg−1 is an effective and safe drug to reduce myoclonus after etomidate without causing any harmful side-effect.

Keywords: adverse effects; anesthetics; etomidate; myoclonus; sufentanil

Document Type: Research Article


Affiliations: 1: Klinik fuer Anesthesiologie und Intensivtherapie, Friedrich-Schiller-Universitaet Jena, Germany, 2: Department of Kinesiology, University of Wisconsin, WI

Publication date: April 1, 2003


Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more